Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1”

384 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 384 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03164616
What this trial is testing

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Who this might be right for
Non Small Cell Lung Cancer NSCLC
AstraZeneca 1,186
Testing effectiveness (Phase 2)UnknownNCT04014101
What this trial is testing

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC
Early research (Phase 1)Study completedNCT02054806
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

Who this might be right for
Solid Tumor
Merck Sharp & Dohme LLC 477
Testing effectiveness (Phase 2)Study completedNCT03631407
What this trial is testing

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Who this might be right for
Colorectal Neoplasms
Merck Sharp & Dohme LLC 41
Not applicableStudy completedNCT03305133
What this trial is testing

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)

Who this might be right for
Large Cell Lung CancerNeuroendocrine Carcinoma of Lung (Diagnosis)
Groupe Francais De Pneumo-Cancerologie 86
Large-scale testing (Phase 3)Active Not RecruitingNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Large-scale testing (Phase 3)Active Not RecruitingNCT03553836
What this trial is testing

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 976
Large-scale testing (Phase 3)Study completedNCT01866319
What this trial is testing

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 834
Testing effectiveness (Phase 2)WithdrawnNCT03167177
What this trial is testing

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Who this might be right for
Melanoma
ImmunityBio, Inc.
Not applicableUnknownNCT03917537
What this trial is testing

WGA in Platinum-refractory HNSCC Underwent Nivolumab

Who this might be right for
HNSCC
Chang Gung Memorial Hospital 80
Large-scale testing (Phase 3)Active Not RecruitingNCT04662710
What this trial is testing

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Who this might be right for
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Merck Sharp & Dohme LLC 895
Testing effectiveness (Phase 2)Study completedNCT02879617
What this trial is testing

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Who this might be right for
Non-Small Cell Lung Cancer NSCLC
Academic Thoracic Oncology Medical Investigators Consortium 47
Testing effectiveness (Phase 2)Study completedNCT02255097
What this trial is testing

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 172
Large-scale testing (Phase 3)Active Not RecruitingNCT05899049
What this trial is testing

Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 249
Large-scale testing (Phase 3)Study completedNCT03361865
What this trial is testing

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Who this might be right for
UC (Urothelial Cancer)
Incyte Corporation 93
Testing effectiveness (Phase 2)Looking for participantsNCT07209189
What this trial is testing

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Who this might be right for
Head and Neck CancerSquamous Cell CarcinomaOral Cavity Cancer+6 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 75
Testing effectiveness (Phase 2)Study completedNCT03284424
What this trial is testing

Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)

Who this might be right for
Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 159
Early research (Phase 1)Study completedNCT05594043
What this trial is testing

MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Who this might be right for
Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC 90
Load More Results